Autologous CD5 CAR T-cells / Beijing GoBroad Hospital - LARVOL DELTA

First-in-human novel bispecific epitope anti-CD5 nanobody CAR-T cells for refractory or relapsed T-cell malignancies. (ASCO 2026) - P1/2 | "We optimized the nanobody NbCD5 CAR construct and showed superior cytotoxicity in vitro and in vivo. We also got preliminary safety and efficacy profiles in r/r T-ALL and T-NHL. This clinical trial is still ongoing, and long-term efficacy and clinical complication of CD5 CAR-T cell therapy still require further investigation."

Bispecific • CAR T-Cell Therapy • First-in-human • IO biomarker • P1 data • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • T Acute Lymphoblastic Leukemia • T Cell Non-Hodgkin Lymphoma • CD7

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies (clinicaltrials.gov) - P1/2 | N=54 | Recruiting | Sponsor: Beijing GoBroad Hospital | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD5

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies (clinicaltrials.gov) - P1/2 | N=54 | Recruiting | Sponsor: Beijing GoBroad Hospital

New P1/2 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2 | N=54 | Recruiting | Sponsor: Beijing GoBroad Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia